Bristol Myers Squibb adding 3 medications on TrumpRx

30.03.26 22:40 Uhr

Werte in diesem Artikel
Aktien

52,52 EUR -0,10 EUR -0,19%

Indizes

PKT PKT

17.959,4 PKT -14,6 PKT -0,08%

3.210,0 PKT 0,4 PKT 0,01%

6.582,7 PKT 7,4 PKT 0,11%

EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned.The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price.The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis.TWO MAJOR DRUG COMPANIES ARE THE LATEST TO JOIN TRUMPRXZeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%.FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTSThe weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price.A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump.The talks with pharmaceutical companies continue to be successful, with more medications added to the government website.Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website.HOUSE GOP SEEKS OFF-RAMP TO SKY-HIGH HEALTH INSURANCE COSTS FOR MILLIONS OF AMERICANSAmgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis.Amgen also lists Aimovig and Repatha for discounts of 62%.GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20.GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%.The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs.GET FOX BUSINESS ON THE GO BY CLICKING HEREUnder the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.Weiter zum vollständigen Artikel bei FOX Business

In eigener Sache

Übrigens: Bristol-Myers Squibb und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: FOX Business

Nachrichten zu Bristol-Myers Squibb Co.

Analysen zu Bristol-Myers Squibb Co.

DatumRatingAnalyst
03.05.2019Bristol-Myers Squibb OverweightBarclays Capital
07.12.2018Bristol-Myers Squibb OutperformBMO Capital Markets
27.04.2018Bristol-Myers Squibb Market PerformBMO Capital Markets
15.02.2018Bristol-Myers Squibb overweightMorgan Stanley
05.05.2017Bristol-Myers Squibb UnderperformBMO Capital Markets
DatumRatingAnalyst
03.05.2019Bristol-Myers Squibb OverweightBarclays Capital
07.12.2018Bristol-Myers Squibb OutperformBMO Capital Markets
27.04.2018Bristol-Myers Squibb Market PerformBMO Capital Markets
15.02.2018Bristol-Myers Squibb overweightMorgan Stanley
29.04.2016Bristol-Myers Squibb BuyUBS AG
DatumRatingAnalyst
28.10.2016Bristol-Myers Squibb HoldDeutsche Bank AG
09.09.2016Bristol-Myers Squibb Equal WeightBarclays Capital
23.05.2016Bristol-Myers Squibb NeutralJ.J.B. Hilliard, W.L. Lyons, Inc.
29.04.2016Bristol-Myers Squibb Equal WeightBarclays Capital
01.12.2015Bristol-Myers Squibb Equal WeightBarclays Capital
DatumRatingAnalyst
05.05.2017Bristol-Myers Squibb UnderperformBMO Capital Markets
27.10.2014Bristol-Myers Squibb SellMKM Partners
25.01.2008Bristol-Myers Squibb DowngradeGoldman Sachs Group Inc.
05.09.2007Bristol-Myers Squibb DowngradeGoldman Sachs Group Inc.
28.09.2006Bristol-Meyers Squibb verkaufenWertpapier

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Bristol-Myers Squibb Co. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen